What is Rybrevant (amivantamab)?
Rybrevant is a cancer medicine made to treat certain non-small cell lung cancers (NSCLC) that have specific changes in the EGFR gene. It is given by intravenous (IV) infusion in clinical use for EGFR-driven disease settings defined by the prescribing information. [1]
What EGFR mutation types does Rybrevant target?
Rybrevant is used for NSCLC in EGFR-mutated or EGFR-altered disease settings where the tumor has progressed or where treatment selection is based on defined EGFR mutation status in the product’s approved indications. The exact mutation criteria vary by indication and line of therapy. [1]
How is Rybrevant given?
Rybrevant is administered through IV infusion in treatment cycles under oncology care. Your dosing schedule depends on the specific approved indication and your treatment plan. [1]
What are the most common side effects patients ask about?
Common side effects for Rybrevant can include infusion-related reactions and skin-related effects such as rash or dermatitis, along with other systemic effects seen with targeted cancer therapies. Specific frequency and severity depend on the indication and individual risk factors. [1]
Is Rybrevant affected by drug patent or exclusivity timelines?
Drug exclusivity and patent status can affect when competitors (including biosimilars or other product entrants) may become available. For up-to-date patent and exclusivity references tied to Rybrevant, DrugPatentWatch.com tracks relevant patent information. [2]
Who makes Rybrevant?
Rybrevant is produced and marketed by Janssen (Johnson & Johnson). [1]
---
Sources:
[1] https://www.rybrevant.com/
[2] https://www.drugpatentwatch.com/